Cognitive impairment is recognized as one of the major long term effects of stroke [1] [2] [3] [4] [5] . In a study of patients with first-ever stroke from the community-based, prospective South London Stroke
Register (SLSR) between 1995 and 2010, the overall age-standardized prevalence of cognitive impairment remained persistently high over time, at 22% up to 15 years after stroke. Similar prevalence rates have also been observed in short follow-up studies 6 . Nevertheless, there are limitations in many follow up studies trying to identify and investigate the potential mechanisms of the association of cognitive impairment with underlying risk factors 7, 8 .
Vascular risk factors are common among stroke patients 8 and control of these underlying vascular risk factors is central to secondary prevention initiatives, not only for reducing the risk of recurrent stroke, but potentially also for reducing the risk of other vascular consequences such as cognitive impairment. Evidence-based pharmacotherapy for secondary stroke prevention, as recommended by guidelines [9] [10] [11] [12] [13] [14] [15] , focuses on modulation of vascular risk factors including antithrombotic treatments and control of blood pressure and lipid levels for a wide spectrum of stroke patients.
In one multicenter randomised clinical trial with over 4 years follow-up and including 6,105 stroke or transient ischaemic attack subjects with a mean blood pressure at the enrollment of 147/86 mmHg 16 , patients who were given combined antihypertensive treatments of angiotensin-converting-enzyme inhibitor and diuretic (perindopril and indapamide) to control blood pressure, had a reduced risk of 19% (95% CI, ) of cognitive deterioration (a decline of 3 or more points in the Mini-Mental State Examination score). However, preliminary results from another multicenter randomised clinical trial involving 20,332 patients with a recent ischaemic stroke and with a mean blood pressure at the randomisation of 144/84 mmHg, did not replicate these findings with angiotensin receptor blockers antihypertensive drugs (telmisartan) of recurrent stroke, but potentially also for reducing the risk of other vascular con on nse e equ qu uen en ence ce ces s s su such as cognitive impairment. Evidence-based pharmacotherapy for secondary stroke prevention, as e eco co omm mm mmen en nde de ded d d by by y g g gui u delines [9] [10] [11] [12] [13] [14] [15] nor with antiplatelet regimens, extended-release dipyridamole plus aspirin or clopidogrel monotherapy 17 . Consequently, there is still no clear evidence on the effect of secondary prevention strategies of vascular risk on long-term cognitive impairment.
The aim of this study is to investigate the relationship between use of secondary prevention drug therapies to control vascular risk in stroke patients and long-term cognitive impairment in patients after first ever stroke and up to 10 years thereafter in a population sample, the SLSR (1995-2011).
Methods

Study Population
The SLSR is a prospective population-based stroke register set up in January 1995, recording all first-ever strokes in patients of all ages for an inner area of South London based on 22 electoral wards in Lambeth and Southwark. Data collected between 1995 and 2010 were used in this analysis. The total source population of the SLSR area was 271,817 individuals, self-reported as 63% White, 28% Black (9% Black Caribbean, 15% Black African, and 4% Black Other), and 9% of Other Ethnic Group in the 2001 census 18 .
Case Ascertainment
Standardised criteria were applied to ensure completeness of case ascertainment, including multiple overlapping sources of notification. All patients with a suspected diagnosis of stroke or transient ischaemic attack documented in different hospital and community based information sources, were investigated for study eligibility. Completeness of case ascertainment has been estimated at 88% by a multinomial-logit capture-recapture model using the methods described elsewhere 18, 19 .
Study Population
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Data Collection
Specially trained study nurses and field workers collected all data prospectively whenever feasible. A study doctor verified the diagnosis of stroke. Patients were examined within 48 hours of referral to SLSR where possible. The following socio-demographic characteristics were collected at initial assessment: self-definition of ethnic origin (census question), stratified into white, black (black Caribbean, black African, and black other), and other ethnic group. The IMD deprivation scores range from 1 to 100 (categorized into quintiles in the an nal al alys ys yse es es); ); ); t t the he he hig ig gh he her the scores the more depriv ved ed ed t th he area.
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or if earlier, clearly in a different vascular territory were included, or if earlier, clearly in a different vascular territory were included.
Vascular risk factors for stroke (either self-reported or from medical notes), prior to and post stroke at each time point, were collected including smoking, hypertension, diabetes mellitus, atrial fibrillation (AF), ischemic heart disease (IHD) (angina pectoris or myocardial infarction), and transient ischemic attack (TIA). Pharmacotherapy for appropriate secondary stroke prevention data were also collected, from the prescribed drugs, at each time point after stroke including antihypertensives (diuretics, angiotensin-converting enzyme inhibitors (ACEI), -blockers, the calcium channel blockers or angiotensin II receptor antagonist), anticoagulants (warfarin or heparin), antiplatelet agents (aspirin, dipyridamole or clopidogrel), diabetes control treatments (oral treatment or insulin) and lipid-lowering drugs (statins, cholesterol absorption inhibitors or fibrates). Since stroke patients often have systemic vascular arteriosclerosis, recommended optimal drug regimen, was defined as a combination of an appropriate antithrombotic treatments with blood pressure and lipid lowering for ischemic strokes and of antihypertensives for hemorrhagic strokes.
Glasgow Coma Score (GCS) 22 dichotomised to < 13 or 13 was used to measure stroke severity at onset and the Barthel Index (BI) 23 scores at annual follow-up with a cut-off of 15 was used to identify patients with moderate (BI = 10-14) to severe disability (BI< 9). Other case-mix indicators used for initial functional neurological deficit included sensory or motor deficits (face, arm, hand or leg), speech deficit (dysarthria, aphasia or dysphasia) and visual deficit (visual field defects or visuo-spatial neglect).
Prior to 1 January 2000 cognitive state was assessed using the Mini-Mental State Exam blockers, the calcium channel blockers or angiotensin II receptor antagonist), ant ntic i icoa o o gu gu gula la ant nt nts s s warfarin or heparin), antiplatelet agents (aspirin, dipyridamole or clopidogrel), diabetes control r rea ea atm tm tme en ents ts ts ( ( (or oral t t tre re reat a ment or insulin) and lipid-lo lo ow we wering drugs (st tat a a ins, s, c c ch ho h lesterol absorption n nhi i ib bitors or fi fibr br brat ates es). ) ). S Sin in ince c ce s str tr trok ok ke e e p pa pat t tie ents of of ften ha ave e s sys yst te em mi mic c va a asc cul ul ular r a art rt ter er rio iosc sc cle le ero ro r si s s s, s, , (MMSE) 24 in the acute phase as well as at follow-ups; after that date the Abbreviated Metal Test (AMT) 25 was used for all assessments. Subjects were defined as cognitively impaired according to predefined cut-off points (MMSE, <24 or AMT, <8) 18 . Patients were assessed at the stroke onset, 3 months and annually after stroke. All follow-up assessments included in the present study were completed by 31 August 2012.
Statistical Analysis
Descriptive analyses were performed at 3 month post-stroke. and TOAST stroke subtypes (LAA, CE, SVO). All multivariate models were adjusted for cognitive function status at 3 months, socio-demographic, case-mix, stroke subtype, and the time-varying covariate, disability, stroke recurrence and vascular risk factors. To assess the factors, were used to determine the baseline RRs of cognitive impairment in pat tie ie ent nt ts s wi wi with th h vascular risk factors. Adjusted RR estimates were conducted using multivariate generalized mo modi di difi fi fied ed ed P P Po oi ois s sson on n r r reg e ression analyses with robu ust st st s st tandard error. To T T i inv nv nve e est s igate the association b be etw w ween short-t-a and nd d l lon on ng-g-g-te e term rm rm c cog og gni ni niti ti t v ve i imp pai ir rme en nt t an nd nd v va as sc cu ula lar r r ri risk sk k f f fac c cto or rs rs, , lo long ng git it tud ud udin inal al al ge gen ne nera ra rali li l ze zed d d e es esti tima ma mati ting ng g e e equ qu q at t tio io i n n n l l log og og-l -lin in nea ea ar r r P P Pois is isso so son n mo mo mode de els ls ls w wit it ith h h r r rob ob bus us u t t t st t tan and da dard rd rd e err rr rro o ors s an n nd d an a an exchangeable le c c cor or o re re rela la l ti ti ion on o m m mat at atri r x x x to to t a a acc cc cou ou ount nt nt f f for or o r rep ep epea ea ate t d d d me me meas as a ur ur ures es e w w wit it thi hi hin n n in in indi divi vi v du du dual al als s s we w re used robustness of the results, we performed additional analyses using multiple imputation of missing data based on inverse probability weights. The probability of response was estimated using multivariable logistic regression including factors associated with dropping out (previous visits cognitive score, age, socio-economic status and ethnicity). This approach had little effect on the estimates. The observed data analysis was therefore used for the present study. Statistical analyses were performed using Stata (2012, StataCorp LP, College Station, Texas).
Ethics
All patients and/or their relatives gave written informed consent to participate in the study, and over the study period very few patients have declined to be registered. 
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Discussion
This study investigated the effect of secondary prevention of stroke (antiplatelet agents, antihypertensive drugs, lipid-lowering and anticoagulants) on long-term cognitive impairment after stroke. To our knowledge, this was the first population-based study to assess the relationship between cognitive impairment and vascular secondary prevention up to 10 years after stroke 26 with different drug regimens 8 . Findings from this study not only provided indicators of potential association between secondary prevention and cognitive impairment, but also helped to improve our understanding of which pharmacotherapies effectively help to treat vascular risk factors and to alter, or to slow down, the progression of cognitive decline following a stroke. The most important observation in our study was that appropriate management of vascular risk factors was associated with improved protective effect of long-term cognitive outcome among stroke patients. Several trials have assessed the effect of stroke secondary prevention drugs on recurrent stroke and survival 27 ; however, the question whether such drugs prevent or delay cognitive decline is still relatively unexplored 8 .
In this study, lipid management after stroke was found to be independently associated with reduced risk of cognitive impairment in most patients regardless of age. This association was observed in short and long term follow-ups with lower risks at 3 months observed among stroke survivors with hypercholesterolaemia, which supports the hypothesis that lipid control therapy may have prevented only the incidence of cognitive impairment in cognitively healthy individuals rather than affect the progression of cognitive decline. Moreover, the lower risks of cognitive impairment at 3 months among stroke survivors with hypercholesterolaemia could be also helped to improve our understanding of which pharmacotherapies effectivel ely y y he he h lp lp p t t to o o tr tr trea ea e t t vascular risk factors and to alter, or to slow down, the progression of cognitive decline following a st st tro ro roke ke ke. Th Th The e mo o ost st st i important observation in our s s stu tud dy was that ap p ppr p p op pri ri ria at ate management of r r v vasc c cul u ar risk fa fact cto or rs s w w was s s as as asso so oci c ciat ated ed ed w wi ith h h im mpr pr rove ed pro o ote te ect ctiv iv i e e e ef ef ffe fect ct o of f f lo o ong ng g-t -t -ter erm m co co cogn gnitiv iv ive e m ou utc tc tcom om ome e am am mo on ong g st stro ro r k ke e p p pat atie ent nt n s. s S S Sev ev ever eral al a t t tri ri ria al als ha ha h ve v ve a ass ss ses es sse se sed d d th th the e ef ef ffe fe fect ct of f f st stro ro roke ke ke s sec ec econ ond da dary ry r prevention d dru ru ugs gs gs o o on n n re re ecu cu curr r re e ent nt nt str tr trok ok o e e e an n nd d d su su surv rv rviv iv ival al l 27 27 27 ; ; ho h h we we weve ve ver, r r t t the he heue ue uest st stio io ion n n wh wh whet et ethe he her r r su su such drugs explained by a carry-over effect of lipid lowering drugs in the primary stroke prevention strategies. These findings support and confirm that continuation of lipid lowering intake after stroke may help to prevent the development of cognitive impairment.
Antihypertensive therapies and optimal medication therapy were strongly associated with beneficial long-term cognitive function in ischemic strokes without history of AF. However, antiplatelet monotherapy use alone was borderline associated with reduction in risk of cognitive impairment. These differences in drug regimens suggest that optimal combination of antithrombotic agents, antihypertensive therapies, and lipid lowering appear to protect patients with ischaemic stroke from cognitive impairment.
Dual antiplatelet therapies and anticoagulants were both associated with a long-term protective effect against cognitive impairment. This finding was also observed in subgroup analyses in ischaemic stroke, which supports that, the prescription of dual antiplatelet therapies with close monitoring for patients who do not tolerate anticoagulant therapy with warfarin could help to prevent cognitive impairment. On the other hand, there is no evidence from this population sample that antihypertensive drugs are associated with reduced cognitive deficit among haemorrhagic stroke and ischaemic strokes with AF.
Out of all combination drug therapies investigated in this study, those associated with a reduction in risk of cognitive impairment were: statins, warfarin, a combination of aspirin and dipyridamole, and diuretics or ACEIs or the combination of a diuretic and an ACEI. Although the choice of specific drugs should be individualized to include consideration of specific patient characteristics, this investigation has provided valuable information on the associated effect of different combinations on the long-term cognitive impairment on a broad spectrum of stroke patients.
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There are some limitations to this study. This prospective population-based study has produced estimates of cognitive status in stroke survivors, but with no comparison with the nonstroke population. Data were based mainly on prescribed drugs without account of patients' systolic blood pressure or lipid profile target levels and we have no information on patients'
adherence to drugs which may attenuate the effect of treatments, particularly in the interaction analyses between different drugs. Also, data about life style changes, such as diet and exercise, which may provide additional cognitive benefits were not included in this study. It was not possible to examine the influence of educational status on cognitive function in this stroke survivor's SLSR register due to missing or not stated education level data. However, we did include socioeconomic status SES of the SLSR patients using Index of Multiple Deprivation, which could serve as a surrogate for educational status, since high SES usually tend to have higher educational levels. Furthermore, the psychometric screening tools used in this study may underestimate the incidence of cognitive impairment, particularly mild cognitive impairment. It has been shown that MMSE or AMT are insensitive to mild cognitive impairment (MCI) and executive function [28] [29] [30] [31] . Despite these limitations in detecting mild cases, this study has shown a protective association with optimal secondary prevention drugs. Similar large long-term studies of post-stroke cognitive function using sensitive tools to detect mild cognitive impairment and executive function, such as the Montreal Cognitive Assessment (MoCA) 28, 32 , would be of benefit to confirm our finding that optimal post stroke pharmacotherapy for secondary prevention could influence the process of cognitive impairment.
In conclusion, controlling vascular risk factors is an important preventive treatment strategy to decrease the risk of stroke recurrence and cognitive impairment. Effective post-stroke secondary prevention could help to prevent or delay the onset of severe global cognitive nclude socioeconomic status SES of the SLSR patients using Index of Multiple e De De Depr pr p iv iv ivat at atio io ion, n, n R which could serve as a surrogate for educational status, since high SES usually tend to have hi igh gh gher er r e edu du duca ca c t t tion n nal al al l levels. Furthermore, the psyc c ch ho hom m metric screeni ing ng n too oo ols ls ls used in this study may u und de derestimate e th th the in inci ci cide de enc nc ce e e of of of c cog og gn ni niti tive ve e im mp pa a airm m men n nt, p p pa ar arti ticu cu cula larl rly mi mild ld ld c cog ogn ni nit ti tive ve i i im mp mpai ai a rm m men en nt. t It ha has s s be be been en e s sho ho hown wn t th ha at t MM MM MMSE SE o o or AM AM AMT T T a ar are e e in in ins se s ns ns nsit iti iv ive e e to o o m m mil il ild d d co co cogn gn nit it tiv iv ive e im im mpa pair ir i m me ment nt nt ( ( (MC MC CI) I) ) a an nd nd executive func nc cti ti ion on n 28 28 28-31 31 31 . . Des es espi pi p te e e t the he hese se s l l lim im imit it i at at a io io ions ns ns i in n n de d d te te ect ct ctin in ing g g mi mi mild ld c c cas as ases es es, , , th th this is s s stu tu tudy dy dy h h has a shown a a impairment. Differences and overlaps of vascular risk factors are common among stroke patients and personalized preventive strategies are critical to alter severe cognitive deficit. Given the high risk of cognitive impairment after stroke, this study shows that optimal preventive intervention and strategic planning are needed in order for health systems to avert or delay the incidence of cognitive decline progression among stroke survivors. 
